AbCellera Biologics Inc. (ABCL) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
AbCellera Biologics Inc. (ABCL) Earnings Overview
As of June 24, 2026, AbCellera Biologics Inc. (ABCL) reported trailing twelve-month net income of -$144M, reflecting +10.9% year-over-year growth. The company earned $-0.47 per diluted share over the past four quarters, with a net profit margin of -194.9%.
Looking at the long-term picture, ABCL's historical earnings data spans multiple years. The company achieved its highest annual net income of $159M in fiscal 2022.
AbCellera Biologics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including TWST (-$81M net income, -20.6% margin), RXRX (-$560M net income, -863.4% margin), SDGR (-$103M net income, -40.4% margin), ABCL has room to improve margins relative to the peer group. Compare ABCL vs TWST →
ABCL Earnings vs Peers
Earnings metrics vs comparable public companies
ABCL Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$146M | +10.1% | -$217M | $-0.49 | -194.9% | -289.0% |
| 2024 | -$163M | -11.2% | -$315M | $-0.55 | -564.8% | -1091.7% |
| 2023 | -$146M | -192.4% | -$237M | $-0.51 | -385.0% | -623.8% |
| 2022 | $159M | +3.3% | $217M | $0.50 | 32.7% | 44.6% |
| 2021 | $153M | +29.1% | $204M | $0.48 | 40.9% | 54.5% |
| 2020 | $119M | +5478.5% | $156M | $0.45 | 51.0% | 66.9% |
| 2019 | -$2M | -815.5% | -$4M | $-0.01 | -19.0% | -35.5% |
| 2018 | $309,000 | - | $-753,000 | $0.00 | 3.5% | -8.5% |
Download Data
Export ABCL earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ABCL — Frequently Asked Questions
Quick answers to the most common questions about buying ABCL stock.
What is ABCL earnings per share (EPS)?
ABCL trailing twelve-month (TTM) diluted EPS is $-0.47, reflecting +10.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is AbCellera Biologics Inc.'s net income?
AbCellera Biologics Inc. (ABCL) trailing twelve-month net income is $-144M as of 2025. Earnings grew +10.9% year-over-year.
Is ABCL profitable?
ABCL is not currently profitable on a TTM basis, reporting a net loss of $-144M. Net margin is -194.9%. Investors should monitor for a return to profitability.
What is ABCL's earnings growth rate?
ABCL compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are ABCL's profit margins?
AbCellera Biologics Inc. net profit margin is -194.9%, operating margin is -289.0%, and gross margin is +61.6%. Below-average margins reflect competitive or cost pressures. Return on Equity is -13.3%.
Is ABCL growing earnings?
ABCL is growing earnings steadily. YoY EPS growth of +10.9% is consistent with the 5-year CAGR of N/A. TTM net income is $-144M.
What was ABCL's best earnings year?
AbCellera Biologics Inc.'s highest annual net income on record is $159M, achieved in fiscal year 2022. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were ABCL's earnings last quarter?
ABCL's most recent reported quarter was Q1 2026. Net income was $-43M with diluted EPS of $-0.14. For a full breakdown of all quarters, see the quarterly earnings table on this page.